cocktails in ex vivo culture medium (eg, stem cell factor, FMS-like tyrosine kinase-3 ligand, thrombopoietin) support generation of inflammatory myeloid cells, and inhibitory factors secreted by these cells impair HSC self-renewal-promoting differentiation. Delta-1 appears to enhance HSC recovery by suppressing inflammatory monocyte production. Because different subsets of monocytes can differentially affect HSC function, it will be important to characterize the ex vivo-generated CD14
1 populations in Inhibitory FcgRIIb and CD20 internalization
In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (eg, rituximab) undergo Fcg receptor IIb (FcgRIIb)-mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based therapeutics (see figure). 5 an effect that may be particularly important in malignancies such as chronic lymphocytic leukemia and mantle cell lymphoma that express high levels of FcgRIIb and show reduced responses to CD20 mAb therapy. CD20 mAbs can be broadly categorized into type I mAbs that induce potent cytotoxicity associated with redistribution of CD20 into Triton X-100-insoluble lipid rafts and type II mAbs that induce cell death. Both type I and type II CD20 mAbs are equally effective at binding opsonized targets to macrophages and eliciting antibody-dependent cellular cytotoxicity. However, type II mAbs were found to be more effective in xenograft tumor studies and syngeneic models of B-cell depletion. 6 To provide insight into the In experiments using Ramos cells transfected with a truncated (nonphosphorylatable) FcgRIIb, the authors were able to definitively identify contributions of cis or trans interactions of FcgRIIb upon activation. Although they found that FcgRIIb expressed in trans could compete with cis-FcgRIIb interactions, they failed to impair internalization of rituximab, an effect that was independent of concentration of rituximab used or levels of FcgRIIb expression. One important conclusion from these findings is that screening the capacity for phosphorylation of FcgRIIb would not adequately predict the rate of CD20 mAb internalization. However, because the rate and extent of internalization and FcgRIIb expression were inversely related, levels of FcgRIIb expression may represent a potential indicator of response to rituximab and thus identify patients for which treatment with type II CD20 antibodies would be preferable. Furthermore, FcgRIIb-mediated internalization of type I CD20 mAbs may lead to preferential clearance of pathogenic cells in systemic lupus erythematosus that express low levels of FcgRIIb, while sparing regulatory B cells that have high levels of expression of CD20, 7 leading to amelioration of autoimmune symptoms. In addition, the negative signaling transduced by FcgRIIb itself may also be beneficial in the context of autoimmunity. More broadly, a critical role for FcgRIIb in mediating the efficacy of therapeutic antibodies directed against a range of tumor targets including tumor necrosis factor receptor (TNFR) superfamily members DR4, DR5, or CD40 has been established. 8, 9 It is likely that involvement of FcgRIIb reduces the potential for FcgR-mediated target cell depletion, enhancing T-cell priming, while minimizing depletion of receptor-bearing cells. Recently, agonistic anti-TNFR antibodies have also been definitively shown to require FcgRIIb for their effects and that this effect is independent of FcgRIIb-mediated signaling. 10 
